This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
by Zacks Equity Research
BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Alcon Stock Gains Following UNITY VCS' Approval in Canada
by Zacks Equity Research
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
by Moumi Mondal
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $134.11, denoting a -1.58% move from the preceding trading day.
Abbott (ABT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion
by Zacks Equity Research
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
by Zacks Equity Research
Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
by Moumi Mondal
HOLX's Molecular Diagnostics growth stays resilient, as new assays and test adoption offset funding headwinds.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $133.67, denoting a -2.71% move from the preceding trading day.
NVST vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Should You Continue to Retain Abbott Stock in Your Portfolio Now?
by Zacks Equity Research
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
by Zacks Equity Research
Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.
The Zacks Analyst Blog Highlights Meta, Palantir, Abbott Laboratories, SandRidge and CompX
by Zacks Equity Research
META, PLTR and ABT lead this week's Zacks blog as AI growth, strong pipelines and solid earnings drive investor interest.
Top Research Reports for Meta Platforms, Palantir & Abbott
by Mark Vickery
META, PLTR, and ABT lead today's top research picks, with strong AI momentum, product innovation, and expanding market share.
DXCM's Access Gains and Operational Strength Offset Margin Pressures
by Zacks Equity Research
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
by Zacks Equity Research
Abbott gains Health Canada approval for its i-STAT TBI test, enabling rapid bedside concussion detection via whole blood.
BSX's Neuromodulation Arm Sees Growth: Q1 Highlights
by Sridatri Sarkar
Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.
Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates
by Zacks Equity Research
Aurora Cannabis (ACB) delivered earnings and revenue surprises of -36.36% and 1.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP